RFK Jr. Moves to Expand Access to Unapproved Peptides
Left 62%
Center 38%
Right 0%
5 left · 3 center · 0 right
What happened
The Department of Health and Human Services, under Secretary Robert F. Kennedy Jr., filed a notice that it will exercise enforcement discretion so compounding pharmacies may prepare six peptides that are not FDA-approved and are not on the FDA bulk-drug substances list: BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500. In July, an FDA advisory panel voted to recommend adding those six peptides to the list, contrary to FDA staff scientists who said there was insufficient evidence they are safe and effective. The policy does not grant FDA approval; it requires patient-specific prescriptions, identity and purity certification, quality testing, and reporting of serious side effects. HHS said the step is meant to offer a regulated alternative to unregulated research-use-only and black-market sales. A related draft policy was opened for public comment and is to remain in place until the FDA finalizes a formal rule.
Sourcing check · Fully on the record · 8 articles
6 of 6 articles cite a named source for the story. It was on the record from the first report.
What these terms mean and how they're counted
- On the record · names a source 6 of 6
- On the record means the article cites a source by name for the story's main claim: a person, or an institution speaking officially, such as a company statement or a named agency's spokesperson. The opposite is an unnamed source. The count is how many of the counted articles cite at least one such source; the names are everyone named across them, each once however the articles spell it. Here: Emily Hilliard, HHS, Robert F Kennedy Jr., Department of Health and Human Services, FDA panel and FDA advisory panel
- Primary evidence · cites a document or data 5 of 6
- Primary evidence means the article cites a record you could check yourself: a court filing or ruling, a dataset or report, a recording or transcript, an official statement or press release, market data. A quote is not a document. The count is how many articles cite one. Here: official notice, agency statement, agency notice, official statement
- Credits another outlet 0 of 6
- The article says the story comes from another outlet's reporting (“first reported by Reuters”). Those articles relay the story; they are not independent confirmation. Here: Each article presents its own reporting.
- Unnamed sources 0 of 6
- The main claim is attributed to people who are not identified: “people familiar with the matter”, “officials said”. The count is how many articles do this.
- How it developed
- When the first report landed and whether it named anyone; when the first named source and the first document appeared. Here: First report Oct 28, 16:13 UTC by NBC News, naming its source. First document in the first report, from NBC News (official notice).
- Not counted 2
- Opinion, analysis and video pieces, and articles too short to assess. Every count above is out of the counted articles. An article republished under a new headline is one article.
This is about who is cited, not whether the story is true. Each source below says what it names. How we count
ONE-SIDED THIS WEEK.
Only left-leaning outlets have covered this story in the last two days;
Daily Caller reported it on 2026-10-16.
Omitted — what each side leaves out
Unpacked
Right-leaning outlets had not covered this as of publication, leaving their readers unaware that compounding pharmacies may now prepare unapproved wellness peptides. Left-leaning coverage reports that HHS will not take legal action against pharmacies that make six peptides still missing from the FDA bulk list. NBC News says those shops can start offering them now, even though agency scientists found insufficient data that the drugs are safe or that they work.
Left-leaning outlets do not agree on whether the change is already in force. ABC News says the peptides became available, while the BBC describes a draft still headed for public comment and notes the plan came from the health secretary rather than the FDA.
Does a prescription written for longer lifespan or better skin meet the patient-specific requirement HHS is using as a safeguard?
Bottom line
Right-leaning readers are missing a live HHS experiment in skipping the bulk-list rule. ABC News says six unapproved wellness peptides became available this week without FDA approval.
The receipts — 4 facts one side's coverage lacks
- HHS will exercise enforcement discretion and not take legal action against compounding pharmacies that make six unapproved peptides, allowing those pharmacies to start offering them now.
- The July FDA advisory panel included six new appointees with ties to the peptide industry.
- There are no published clinical trials that provide evidence that these specific peptides are effective in humans for any condition.
- In 2023, the FDA classified 19 peptides as unsafe to be compounded.
The Left View
NBC News, ABC News, The Hill, and the BBC report that Kennedy is loosening restrictions on unapproved wellness peptides promoted online for healing, skin, longevity, and muscle. They stress that none of the six substances have FDA approval or published human trials proving they work, that FDA scientists opposed the July recommendation, and that the advisory panel included new members with peptide-industry ties. Coverage quotes critics including former FDA official Peter Lurie, who said the agency is turning a blind eye, and Shabbir Safdar of the Partnership for Safe Medicines, who called the compounds untested and dangerous. Outlets also carry HHS’s stated rationale: moving patients off a gray market toward compounding pharmacies that must test ingredients and report adverse events. ABC and the BBC note the peptides’ popularity among influencers and on TikTok, and that Kennedy has described himself as a fan of the drugs.
Our Take (balanced)
The story is substantive: it rests on a named HHS notice and draft policy, a specific list of six peptides, a documented July advisory-panel vote, and on-the-record statements from HHS and named critics. Established facts are that the six peptides are not FDA-approved, that HHS is using enforcement discretion rather than finishing the usual bulk-list rulemaking first, that pharmacies must meet testing and reporting conditions, and that FDA staff previously found insufficient safety and efficacy data. What remains contested is whether the peptides are safe or effective in humans, whether industry-tied panel members improperly influenced the July vote, and whether compounding will reduce gray-market risk. No right-leaning outlet has reported this. Watch for the public-comment docket, any proposed FDA bulk-list rule, compounding pharmacies actually offering the six peptides, and subsequent adverse-event reports.
8 sources
- RFK Jr. takes shortcut to make some unapproved peptides available for use
- HHS to allow sale of unapproved peptides under review
- Some wellness peptides will become widely available, HHS says
- US Health Secretary RFK Jr to expand access to unapproved peptides
- WATCH: HHS says some wellness peptides will be available by prescription
- Dr. Jon LaPook explains why peptide sales are controversial
- RFK Jr. to ease access to unapproved peptides, draft policy states
- Inside RFK Jr.'s push for pharmacies to make non-FDA approved peptides
More stories
The week's bottom lines, in your inbox
One email a week: the five stories that mattered and what they actually mean. Free.